Showing 1 posts of 1 posts found.
NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO